Beauty Health (NASDAQ:SKIN) Stock Price Expected to Rise, TD Cowen Analyst Says

Beauty Health (NASDAQ:SKIN) had its target price lifted by analysts at TD Cowen from $2.00 to $2.50 in a report issued on Monday,Benzinga reports. The firm presently has a “hold” rating on the stock. TD Cowen’s price target indicates a potential upside of 14.68% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. Wall Street Zen upgraded shares of Beauty Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Stifel Nicolaus boosted their price target on shares of Beauty Health from $3.00 to $4.00 and gave the stock a “hold” rating in a research report on Friday, August 1st. Finally, Roth Capital assumed coverage on shares of Beauty Health in a research report on Friday, September 19th. They set a “buy” rating and a $3.50 price target on the stock. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Beauty Health has a consensus rating of “Hold” and a consensus target price of $2.81.

Beauty Health Stock Performance

SKIN opened at $2.18 on Monday. The firm has a market capitalization of $276.47 million, a PE ratio of -7.79 and a beta of 1.23. Beauty Health has a twelve month low of $0.78 and a twelve month high of $2.69. The firm’s 50-day moving average price is $2.03 and its 200 day moving average price is $1.66. The company has a current ratio of 5.15, a quick ratio of 4.15 and a debt-to-equity ratio of 4.91.

Beauty Health (NASDAQ:SKIN) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The firm had revenue of $78.20 million for the quarter, compared to analyst estimates of $74.67 million. Beauty Health had a negative net margin of 6.13% and a negative return on equity of 32.82%. Beauty Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts expect that Beauty Health will post -0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Beauty Health

Large investors have recently added to or reduced their stakes in the business. Soleus Capital Management L.P. acquired a new stake in Beauty Health during the 2nd quarter worth $1,910,000. Millennium Management LLC boosted its stake in Beauty Health by 30.6% during the 4th quarter. Millennium Management LLC now owns 3,118,970 shares of the company’s stock worth $4,959,000 after purchasing an additional 730,647 shares during the period. Mirabella Financial Services LLP boosted its stake in Beauty Health by 5.0% during the 2nd quarter. Mirabella Financial Services LLP now owns 12,861,549 shares of the company’s stock worth $24,566,000 after purchasing an additional 614,602 shares during the period. Geode Capital Management LLC boosted its stake in Beauty Health by 27.5% during the 2nd quarter. Geode Capital Management LLC now owns 2,302,784 shares of the company’s stock worth $4,399,000 after purchasing an additional 496,963 shares during the period. Finally, Prescott Group Capital Management L.L.C. boosted its stake in Beauty Health by 47.0% during the 1st quarter. Prescott Group Capital Management L.L.C. now owns 646,798 shares of the company’s stock worth $867,000 after purchasing an additional 206,798 shares during the period. 93.26% of the stock is owned by hedge funds and other institutional investors.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.